home · filing · 0001493152-24-031862
8-K filed August 14, 2024, 7:59 PM ET
ticker ABEO
CIK 0000318306
leadership
confidence high
sentiment positive
materiality 0.50
Abeona Therapeutics appoints Drs. Zeiher and Crombez to Board of Directors
ABEONA THERAPEUTICS INC.
Bernhardt G. Zeiher, MD appointed as Class 1 director; Eric Crombez, MD as Class 2 director; both independent.
Zeiher is former CMO of Astellas Pharma with 20+ years of drug development; Crombez is CMO of Ultragenyx and FDA advisory committee member.
Each director receives $50,000 annual cash retainer and $55,000 one-time RSAs with one-year vesting.
Appointments effective August 8, 2024 (Zeiher) and August 12, 2024 (Crombez).
Additions come as Abeona focuses on pz-cel gene therapy for RDEB and pipeline expansion.
Executive movements
Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements .
Effective 2024-08-12
Filed August 14, 2024, 7:59 PM ET
appointed Bernhardt G. Zeiher, MD, FCCP, FACP, on August 8, 2024 and Eric Crombez, MD on August 12, 2024 as members of the Board of the Company.
Effective 2024-08-08
Filed August 14, 2024, 7:59 PM ET
appointed Bernhardt G. Zeiher, MD, FCCP, FACP, on August 8, 2024 and Eric Crombez, MD on August 12, 2024 as members of the Board of the Company.
Key facts
Extracted from this filing and checked against the source text.
Executive change
SEC 8-K Item 5.02
confidence 0.95
Eric Crombez was appointed as Director at ABEONA THERAPEUTICS INC..
Action appointed
Role Director
Exact text from the filing
appointed Bernhardt G. Zeiher, MD, FCCP, FACP, on August 8, 2024 and Eric Crombez, MD on August 12, 2024 as members of the Board of the Company.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Bernhardt G. Zeiher was appointed as Director at ABEONA THERAPEUTICS INC..
Action appointed
Role Director
Exact text from the filing
appointed Bernhardt G. Zeiher, MD, FCCP, FACP, on August 8, 2024 and Eric Crombez, MD on August 12, 2024 as members of the Board of the Company.
View on SEC.gov
Source: SEC EDGAR
accession 0001493152-24-031862
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.